Turn off MathJax
Article Contents
Ya-Ling Zhu, Lei-Lei Meng, Jin-Hu Ma, Xin Yuan, Shu-Wen Chen, Xin-Rui Yi, Xin-Yu Li, Yi Wang, Yun-Shu Tang, Min Xue, Mei-Zi Zhu, Jin Peng, Xue-Jin Lu, Jian-Zhen Huang, Zi-Chen Song, Chong Wu, Ke-Zhong Zheng, Qing-Qing Dai, Fan Huang, Hao-Shu Fang. Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease. Zoological Research, 2024, 45(1): 79-94. doi: 10.24272/j.issn.2095-8137.2023.022
Citation: Ya-Ling Zhu, Lei-Lei Meng, Jin-Hu Ma, Xin Yuan, Shu-Wen Chen, Xin-Rui Yi, Xin-Yu Li, Yi Wang, Yun-Shu Tang, Min Xue, Mei-Zi Zhu, Jin Peng, Xue-Jin Lu, Jian-Zhen Huang, Zi-Chen Song, Chong Wu, Ke-Zhong Zheng, Qing-Qing Dai, Fan Huang, Hao-Shu Fang. Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease. Zoological Research, 2024, 45(1): 79-94. doi: 10.24272/j.issn.2095-8137.2023.022

Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease

doi: 10.24272/j.issn.2095-8137.2023.022
The raw data reported in this paper were deposited in the National Center for Biotechnology Information Sequence Read Archive (NCBI SRA: PRJNA1044849), National Genomics Data Center (GSA: PRJCA017968 and PRJCA002667), and Science Data Bank (DOI:10.57760/sciencedb.09322). All data that support the findings of this study are available from the corresponding authors upon request.
The authors declare they have no competing interests.
H.S.F. and F.H. designed the experiments. Y.L.Z., L.L.M., and J.H.M. performed the experiments and completed the manuscript. X.Y., Y.S.T., M.X., and S.W.C. performed the cell experiments. X.R.Y. and X.Y.L. preformed animal experiments. Y.W. and M.Z.Z. analyzed the H3K27ac ChIP-Seq and RNA-Seq data. J.P. and X.J.L. conducted the core transcription factor prediction. J.Z.H. conducted the integrative ChIP-Seq and RNA-Seq analyses. Z.C.S., C.W., K.Z.Z., and Q.Q.D. analyzed most of the experimental data. All authors read and approved the final version of the manuscript.
#Authors contributed equally to this work
Funds:  This study was supported by the National Natural Science Foundation of China (81971875, 82300661), Natural Science Foundation of Anhui province (2308085QH246), Natural Science Foundation of the Anhui Higher Education Institutions (KJ2021A0205), Basic and Clinical Cooperative Research Program of Anhui Medical University (2019xkjT002, 2019xkjT022, 2022xkjT013), Talent Training Program, School of Basic Medical Sciences, Anhui Medical University (2022YPJH102), and National College Students Innovation and Entrepreneurship Training Program of China (202210366024)
More Information
  • Non-alcoholic fatty liver disease (NAFLD) is associated with mutations in lipopolysaccharide-binding protein (LBP), but the underlying epigenetic mechanisms remain understudied. Herein, LBP-/- rats with NAFLD were established and used to conduct integrative targeting-active enhancer histone H3 lysine 27 acetylation (H3K27ac) chromatin immunoprecipitation coupled with high-throughput and transcriptomic sequencing analysis to explore the potential epigenetic pathomechanisms of active enhancers of NAFLD exacerbation upon LBP deficiency. Notably, LBP-/- reduced the inflammatory response but markedly aggravated high-fat diet (HFD)-induced NAFLD in rats, with pronounced alterations in the histone acetylome and regulatory transcriptome. In total, 1 128 differential enhancer-target genes significantly enriched in cholesterol and fatty acid metabolism were identified between wild-type (WT) and LBP-/- NAFLD rats. Based on integrative analysis, CCAAT/enhancer-binding protein β (C/EBPβ) was identified as a pivotal transcription factor (TF) and contributor to dysregulated histone acetylome H3K27ac, and the lipid metabolism gene SCD was identified as a downstream effector exacerbating NAFLD. This study not only broadens our understanding of the essential role of LBP in the pathogenesis of NAFLD from an epigenetics perspective but also identifies key TF C/EBPβ and functional gene SCD as potential regulators and therapeutic targets.
  • The raw data reported in this paper were deposited in the National Center for Biotechnology Information Sequence Read Archive (NCBI SRA: PRJNA1044849), National Genomics Data Center (GSA: PRJCA017968 and PRJCA002667), and Science Data Bank (DOI:10.57760/sciencedb.09322). All data that support the findings of this study are available from the corresponding authors upon request.
    The authors declare they have no competing interests.
    H.S.F. and F.H. designed the experiments. Y.L.Z., L.L.M., and J.H.M. performed the experiments and completed the manuscript. X.Y., Y.S.T., M.X., and S.W.C. performed the cell experiments. X.R.Y. and X.Y.L. preformed animal experiments. Y.W. and M.Z.Z. analyzed the H3K27ac ChIP-Seq and RNA-Seq data. J.P. and X.J.L. conducted the core transcription factor prediction. J.Z.H. conducted the integrative ChIP-Seq and RNA-Seq analyses. Z.C.S., C.W., K.Z.Z., and Q.Q.D. analyzed most of the experimental data. All authors read and approved the final version of the manuscript.
    #Authors contributed equally to this work
  • loading
  • [1]
    Abuín JM, Pichel JC, Pena TF, et al. 2015. BigBWA: approaching the burrows-wheeler aligner to big data technologies. Bioinformatics, 31(24): 4003−4005. doi: 10.1093/bioinformatics/btv506
    [2]
    Becares N, Gage MC, Voisin M, et al. 2019. Impaired LXRα phosphorylation attenuates progression of fatty liver disease. Cell Reports, 26(4): 984−995.e6. doi: 10.1016/j.celrep.2018.12.094
    [3]
    Brunt EM, Kleiner DE, Wilson LA, et al. 2011. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 53(3): 810−820. doi: 10.1002/hep.24127
    [4]
    Dobin A, Davis CA, Schlesinger F, et al. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29(1): 15−21. doi: 10.1093/bioinformatics/bts635
    [5]
    Dobrzyn P, Dobrzyn A, Miyazaki M, et al. 2004. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proceedings of the National Academy of Sciences of the United States of America, 101(17): 6409−6414.
    [6]
    Dörr D, Obermayer B, Weiner JM, et al. 2022. C/EBPβ regulates lipid metabolism and Pparg isoform 2 expression in alveolar macrophages. Science Immunology, 7(75): eabj0140. doi: 10.1126/sciimmunol.abj0140
    [7]
    Feinberg AP. 2007. Phenotypic plasticity and the epigenetics of human disease. Nature, 447(7143): 433−440. doi: 10.1038/nature05919
    [8]
    Feng S, Reuss L, Wang Y. 2016. Potential of natural products in the inhibition of adipogenesis through regulation of PPARγ expression and/or its transcriptional activity. Molecules, 21(10): 1278. doi: 10.3390/molecules21101278
    [9]
    Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 24(7): 908−922. doi: 10.1038/s41591-018-0104-9
    [10]
    Hsieh WC, Sutter BM, Ruess H, et al. 2022. Glucose starvation induces a switch in the histone acetylome for activation of gluconeogenic and fat metabolism genes. Molecular Cell, 82(1): 60−74.e5. doi: 10.1016/j.molcel.2021.12.015
    [11]
    Hu MJ, Long M, Dai RJ. 2022. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Molecular and Cellular Biochemistry, 477(1): 191−203. doi: 10.1007/s11010-021-04269-0
    [12]
    Jin CJ, Engstler AJ, Ziegenhardt D, et al. 2017. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice. Journal of Gastroenterology and Hepatology, 32(3): 708−715. doi: 10.1111/jgh.13488
    [13]
    Kim E, Lee JH, Ntambi JM, et al. 2011. Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro. European Journal of Pharmacology, 672(1–3): 38–44.
    [14]
    Klepp TD, Sloan ME, Soundararajan S, et al. 2022. Elevated stearoyl-CoA desaturase 1 activity is associated with alcohol-associated liver disease. Alcohol, 102: 51−57. doi: 10.1016/j.alcohol.2022.04.001
    [15]
    Lambert SA, Jolma A, Campitelli LF, et al. 2018. The human transcription factors. Cell, 172(4): 650−665. doi: 10.1016/j.cell.2018.01.029
    [16]
    Li H, Handsaker B, Wysoker A, et al. 2009. The sequence alignment/map format and SAMtools. Bioinformatics, 25(16): 2078−2079. doi: 10.1093/bioinformatics/btp352
    [17]
    Li XZ, Yuan BC, Lu M, et al. 2021. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nature Communications, 12(1): 7213. doi: 10.1038/s41467-021-27539-3
    [18]
    Liang N, Damdimopoulos A, Goñi S, et al. 2019. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα. Nature Communications, 10(1): 1684. doi: 10.1038/s41467-019-09524-z
    [19]
    Liu Y, Jiang L, Sun CX, et al. 2018. Insulin/snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis. Nature Communications, 9(1): 2751. doi: 10.1038/s41467-018-05309-y
    [20]
    Love MI, Huber W, Anders S. 2014. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12): 550. doi: 10.1186/s13059-014-0550-8
    [21]
    Marzi SJ, Leung SK, Ribarska T, et al. 2018. A histone acetylome-wide association study of Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex. Nature Neuroscience, 21(11): 1618−1627. doi: 10.1038/s41593-018-0253-7
    [22]
    Meng LL, Song ZC, Liu AD, et al. 2021. Effects of lipopolysaccharide-binding protein (LBP) single nucleotide polymorphism (SNP) in infections, inflammatory diseases, metabolic disorders and cancers. Frontiers in Immunology, 12: 681810. doi: 10.3389/fimmu.2021.681810
    [23]
    Moreno-Navarrete JM, Escoté X, Ortega F, et al. 2015. Lipopolysaccharide binding protein is an adipokine involved in the resilience of the mouse adipocyte to inflammation. Diabetologia, 58(10): 2424−2434. doi: 10.1007/s00125-015-3692-7
    [24]
    Moseti D, Regassa A, Kim WK. 2016. Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules. International Journal of Molecular Sciences, 17(1): 124. doi: 10.3390/ijms17010124
    [25]
    Nien HC, Sheu JC, Chi YC, et al. 2018. One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis. Plos One, 13(11): e0207882. doi: 10.1371/journal.pone.0207882
    [26]
    Ntambi JM, Miyazaki M, Stoehr JP, et al. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proceedings of the National Academy of Sciences of the United States of America, 99(17): 11482−11486.
    [27]
    Ospelt C. 2022. A brief history of epigenetics. Immunology Letters, 249: 1−4. doi: 10.1016/j.imlet.2022.08.001
    [28]
    Pfalzgraff A, Weindl G. 2019. Intracellular lipopolysaccharide sensing as a potential therapeutic target for sepsis. Trends in Pharmacological Sciences, 40(3): 187−197. doi: 10.1016/j.tips.2019.01.001
    [29]
    Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 26(6): 841−842. doi: 10.1093/bioinformatics/btq033
    [30]
    Rada-Iglesias A, Bajpai R, Swigut T, et al. 2011. A unique chromatin signature uncovers early developmental enhancers in humans. Nature, 470(7333): 279−283. doi: 10.1038/nature09692
    [31]
    Samuel VT, Shulman GI. 2018. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metabolism, 27(1): 22−41. doi: 10.1016/j.cmet.2017.08.002
    [32]
    Sewe SO, Silva G, Sicat P, et al. 2022. Trimming and validation of illumina short reads using trimmomatic, trinity assembly, and assessment of RNA-seq data. In: Edwards D. Plant Bioinformatics: Methods and Protocols. New York: Springer, 211–232.
    [33]
    Smith E, Shilatifard A. 2014. Enhancer biology and enhanceropathies. Nature Structural & Molecular Biology, 21(3): 210−219.
    [34]
    Soneson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research, 4: 1521. doi: 10.12688/f1000research.7563.1
    [35]
    Song ZC, Meng LL, He ZX, et al. 2021. LBP protects hepatocyte mitochondrial function via the PPAR-CYP4A2 signaling pathway in a rat sepsis model. Shock, 56(6): 1066−1079. doi: 10.1097/SHK.0000000000001808
    [36]
    Sun C, Fan JG, Qiao L. 2015. Potential epigenetic mechanism in non-alcoholic fatty liver disease. International Journal of Molecular Sciences, 16(3): 5161−5179.
    [37]
    Sun L, Yu ZJ, Ye XW, et al. 2010. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care, 33(9): 1925−1932. doi: 10.2337/dc10-0340
    [38]
    Szklarczyk D, Morris JH, Cook H, et al. 2017. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Research, 45(D1): D362−D368. doi: 10.1093/nar/gkw937
    [39]
    Takagi H, Tamura I, Fujimura T, et al. 2022. Transcriptional coactivator PGC-1α contributes to decidualization by forming a histone-modifying complex with C/EBPβ and p300. Journal of Biological Chemistry, 298(5): 101874. doi: 10.1016/j.jbc.2022.101874
    [40]
    Takahashi JS, Kumar V, Nakashe P, et al. 2015. ChIP-seq and RNA-seq methods to study circadian control of transcription in mammals. Methods in Enzymology, 551: 285−321.
    [41]
    Takeuchi F, Yanai K, Inomata H, et al. 2007. Search of type 2 diabetes susceptibility gene on chromosome 20q. Biochemical and Biophysical Research Communications, 357(4): 1100−1106. doi: 10.1016/j.bbrc.2007.04.063
    [42]
    Tamura I, Maekawa R, Jozaki K, et al. 2021. Transcription factor C/EBPβ induces genome-wide H3K27ac and upregulates gene expression during decidualization of human endometrial stromal cells. Molecular and Cellular Endocrinology, 520: 111085. doi: 10.1016/j.mce.2020.111085
    [43]
    Villar D, Berthelot C, Aldridge S, et al. 2015. Enhancer evolution across 20 mammalian species. Cell, 160(3): 554−566. doi: 10.1016/j.cell.2015.01.006
    [44]
    Whyte WA, Orlando DA, Hnisz D, et al. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell, 153(2): 307−319. doi: 10.1016/j.cell.2013.03.035
    [45]
    Xi Y, Shen WJ, Ma LL, et al. 2016. HMGA2 promotes adipogenesis by activating C/EBPβ-mediated expression of PPARγ. Biochemical and Biophysical Research Communications, 472(4): 617−623. doi: 10.1016/j.bbrc.2016.03.015
    [46]
    Yang X, Sun DT, Xiang H, et al. 2021. Hepatocyte SH3RF2 deficiency is a key aggravator for NAFLD. Hepatology, 74(3): 1319−1338. doi: 10.1002/hep.31863
    [47]
    Younossi Z, Tacke F, Arrese M, et al. 2019. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 69(6): 2672−2682. doi: 10.1002/hep.30251
    [48]
    Youssefian L, Vahidnezhad H, Saeidian AH, et al. 2019. Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. Journal of Hepatology, 71(2): 366−370. doi: 10.1016/j.jhep.2019.03.026
    [49]
    Yu Y, Cai JJ, She ZG, et al. 2019. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Advanced Science, 6(4): 1801585. doi: 10.1002/advs.201801585
    [50]
    Zhang N, Wang YL, Zhang JL, et al. 2020. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1. The FASEB Journal, 34(11): 15338−15363. doi: 10.1096/fj.202000836RR
    [51]
    Zhang Y, Liu T, Meyer CA, et al. 2008. Model-based analysis of ChIP-seq (MACS). Genome Biology, 9(9): R137. doi: 10.1186/gb-2008-9-9-r137
    [52]
    Zhao N, Zhang XX, Ding JJ, et al. 2022a. SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface. JCI insight, 7(15): e154113. doi: 10.1172/jci.insight.154113
    [53]
    Zhao S, Zhang XR, Li HT. 2018. Beyond histone acetylation—writing and erasing histone acylations. Current Opinion in Structural Biology, 53: 169−177. doi: 10.1016/j.sbi.2018.10.001
    [54]
    Zhao YC, Gao LC, Jiang CL, et al. 2022b. The transcription factor zinc fingers and homeoboxes 2 alleviates NASH by transcriptional activation of phosphatase and tensin homolog. Hepatology, 75(4): 939−954. doi: 10.1002/hep.32165
    [55]
    Zheng RB, Wan CX, Mei SL, et al. 2019. Cistrome data browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Research, 47(D1): D729−D735. doi: 10.1093/nar/gky1094
    [56]
    Zhou Z, Xu MJ, Gao B. 2016. Hepatocytes: a key cell type for innate immunity. Cellular & Molecular Immunology, 13(3): 301−315.
    [57]
    Zhu YL, Zeng QJ, Li F, et al. 2021. Dysregulated H3K27 acetylation is implicated in fatty liver hemorrhagic syndrome in chickens. Frontiers in Genetics, 11: 574167. doi: 10.3389/fgene.2020.574167
  • ZR-2023-022-Supplementary Materials.pdf
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)

    Article Metrics

    Article views (416) PDF downloads(56) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return